T-Cell Vaccination in Multiple Sclerosis (MS)
Phase 1
- Conditions
- Multiple Sclerosis
- Registration Number
- NCT00220428
- Lead Sponsor
- Sheba Medical Center
- Brief Summary
The purpose of this study is to evaluate the safety of T-cell vaccination in MS patients.
- Detailed Description
Immunization of MS patients with irradiated autologous encephalitogenic myelin peptides (EMP) specific T-cell lines or clones.
Clinical immunologic and neuroradiologic evaluation.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- Definite MS (post criteria)
- Relapsing remitting or primary progressive clinical course. At least one relapse in the last two years.
- Disease duration > 1 year
- Expanded Disability Status Scale (EDSS) between 0-6
- Brain magnetic resonance imaging (MRI) compatible with MS
- Not involved in any other clinical trials
- No other systemic disease
Exclusion Criteria
- Does not comply with the above
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method safety assessment of T-cell vaccination in nonresponding MS patients
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Multiple Sclerosis Center
🇮🇱Ramat Gan, Israel